Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2555
Abstract: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. read more here.
Keywords: adapted treatment; response adapted; treatment rituximab; rituximab bendamustine ... See more keywords
COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.174_2880
Abstract: TPS7573Background: Patients (pts) with iNHL treated with front-line immunochemotherapy may benefit from an alternative, chemotherapy-free regimen at relapse. Zandelisib, a potent, selective, and st... read more here.
Keywords: immunochemotherapy; study pi3k; coastal phase; inhibitor zandelisib ... See more keywords
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2378
Abstract: Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive… read more here.
Keywords: lymphoma; predictive factors; immunochemotherapy; follicular lymphoma ... See more keywords
Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-54371-8
Abstract: Until now, there are still few comparisons between neoadjuvant immunochemotherapy and chemotherapy as first-line treatment for patients with stage IB-IIIB lung squamous cell carcinoma (LUSC). In addition, the ability of pathologic response to predict long-term… read more here.
Keywords: survival; response; group; chemotherapy ... See more keywords
Blaschko-linear Acquired Inflammatory Skin Eruption (BLAISE) observed in a breast cancer patient under immunochemotherapy.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llaf379
Abstract: A case of unilateral BLASE observed in a 28-year-old woman after a second course of immunochemotherapy treatment for breast cancer, successfully treated with tapered systemic prednisolone. read more here.
Keywords: breast cancer; blaschko linear; linear acquired; immunochemotherapy ... See more keywords
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17513
Abstract: Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front‐line ‘attenuated’ or low‐intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients… read more here.
Keywords: immunochemotherapy; analysis; mantle cell; dose ... See more keywords
LaSap vaccine: Immunotherapy and immunochemotherapy associated with allopurinol in dogs naturally infected with Leishmania infantum
Sign Up to like & getrecommendations! Published in 2024 at "Parasite Immunology"
DOI: 10.1111/pim.13028
Abstract: Canine visceral leishmaniasis is a parasitic zoonosis that has a profound impact on public health in countries where it is endemic. Chemotherapeutic treatments cannot keep dogs stable for long periods, and the risk of generating… read more here.
Keywords: immunotherapy; leishmania infantum; naturally infected; lasap vaccine ... See more keywords
Attention-guided framework for integrative omics and temporal dynamics in predicting major pathological response in neoadjuvant immunochemotherapy for NSCLC
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2025-012526
Abstract: Objective This study developed a multiomics model combining radiomics, pathomics, and temporal imaging to predict major pathological response in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunochemotherapy. Methods A retrospective, multicenter… read more here.
Keywords: neoadjuvant immunochemotherapy; pathological response; model; immunochemotherapy ... See more keywords
Comparative efficacy and safety of obinutuzumab- versus rituximab-based immunochemotherapy in newly diagnosed burkitt lymphoma: A single-center retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-6886
Abstract: Background: Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy requiring intensive immunochemotherapy. While rituximab(R)combined with regimens like DA-EPOCH has improved outcomes, resistance and toxicity remain challenges. Obinutuzumab(G), a glycoengineered type II anti-CD20 monoclonal antibody,… read more here.
Keywords: pfs; burkitt lymphoma; rituximab; immunochemotherapy ... See more keywords
Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cancer"
DOI: 10.1186/s12885-024-12333-3
Abstract: The optimal timing for surgery following neoadjuvant immunochemotherapy for lung squamous cell carcinoma appears to be a topic of limited data. Many clinical studies lack stringent guidelines regarding this timing. The objective of this study… read more here.
Keywords: treatment; neoadjuvant immunochemotherapy; squamous cell; immunochemotherapy ... See more keywords
Predictive model of postoperative pneumonia after neoadjuvant immunochemotherapy for esophageal cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-22-149
Abstract: Background Postoperative pneumonia (PP) is the most common pulmonary complication of esophagectomy. It is of great importance to identify any high-risk factors and prevent pulmonary complications to improve the prognosis of patients with esophageal cancer… read more here.
Keywords: esophageal cancer; postoperative pneumonia; immunochemotherapy; neoadjuvant immunochemotherapy ... See more keywords